How to buy Zoetis (ZTS) stocks

Zoetis is a drug manufacturers - specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $164.84 – a decrease of 7.49% over the previous week. Zoetis employs 14,100 staff and has a trailing 12-month revenue of around $9.2 billion.

Our top picks for where to buy Zoetis stock

Buy Zoetis stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Zoetis stock price (NYSE: ZTS)

Use our graph to track the performance of ZTS stocks over time.

Zoetis stocks at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$164.84
52-week range	$144.11 - $199.86
50-day moving average more info button	$180.22
200-day moving average more info button	$176.93
Wall St. target price	$214.22
PE ratio more info button	31.334
Dividend yield more info button	$1.671 (1.2%)
Earnings per share (TTM) more info button	$5.33

Is it a good time to buy Zoetis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Zoetis price performance over time

Historical closes compared with the close of $163.52 from 2024-12-19

1 week (2024-12-13)	-8.23%
1 month (2024-11-21)	-7.46%
3 months (2024-09-20)	-15.12%
6 months (2024-06-21)	-4.42%

1 year (2023-12-21)	-16.00%
2 years (2022-12-21)	14.99%
3 years (2021-12-21)	231.484
5 years (2019-12-20)	27.95%

Is Zoetis stock undervalued or overvalued?

Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zoetis's P/E ratio

Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Zoetis shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Zoetis's PEG ratio

Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5977. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Zoetis's EBITDA

Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.8 billion.

The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.

Zoetis financials

Revenue TTM	$9.2 billion
Operating margin TTM	38.53%
Gross profit TTM	$5.6 billion
Return on assets TTM	14.66%
Return on equity TTM	47.3%
Profit margin	26.55%
Book value	$11.59
Market Capitalization more info button	$75.3 billion

TTM: trailing 12 months

Zoetis stock dividends

Dividend payout ratio: 30% of net profits

Recently Zoetis has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $1.671 per share.

While Zoetis's payout ratio might seem fairly standard, it's worth remembering that Zoetis may be investing much of the rest of its net profits in future growth.

Zoetis's most recent dividend payout was on 3 March 2025. The latest dividend was paid out to all shareholders who bought their stocks by 20 January 2025 (the "ex-dividend date").

Zoetis stock price volatility

Over the last 12 months, Zoetis's stocks have ranged in value from as little as $144.1149 up to $199.8564. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.896. This would suggest that Zoetis's stocks are less volatile than average (for this exchange).

Zoetis overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Zoetis is owned by insiders or institutions?
Currently 0.203% of Zoetis stocks are held by insiders and 95.831% by institutions. How many people work for Zoetis?
Latest data suggests 14,100 work at Zoetis. When does the fiscal year end for Zoetis?
Zoetis's fiscal year ends in December. Where is Zoetis based?
Zoetis's address is: 10 Sylvan Way, Parsippany, NJ, United States, 07054 What is Zoetis's ISIN number?
Zoetis's international securities identification number is: US98978V1035 What is Zoetis's CUSIP number?
Zoetis's Committee on Uniform Securities Identification Procedures number is: 98978V103

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.